Literature DB >> 2865027

Assessment of dezocine for morphine-like subjective effects and miosis.

D R Jasinski, K L Preston.   

Abstract

Dezocine is an analgesic soon to be marketed in the United States. In this study we examined the abuse potential of dezocine. Subjective and miotic effects of single subcutaneous doses of dezocine, morphine, and placebo were assessed under double-blind conditions in 10 adult male nondependent drug abusers. Dezocine and morphine were equipotent in inducing a constellation of effects typical of opioid agonists, including miosis and increases in opioid signs and symptoms, liking, and euphoria. Both drugs were consistently identified by subjects as being "dope" (opiates). Thus the profile of effects of single doses of dezocine indicate that the drug has the potential to be abused. However, the agonist-antagonist activities of dezocine demonstrated by others suggest that its abuse potential is less than that of morphine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865027     DOI: 10.1038/clpt.1985.221

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J J O'Brien; P Benfield
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

2.  Subjective and behavioral responses to intravenous fentanyl in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; J G Zaragoza; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition.

Authors:  Yong-Xiang Wang; Xiao-Fang Mao; Teng-Fei Li; Nian Gong; Ma-Zhong Zhang
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

4.  Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.

Authors:  Yu-Hua Wang; Jing-Rui Chai; Xue-Jun Xu; Ru-Feng Ye; Gui-Ying Zan; George Yun-Kun Liu; Jian-Dong Long; Yan Ma; Xiang Huang; Zhi-Chao Xiao; Hu Dong; Yu-Jun Wang
Journal:  Sci Rep       Date:  2018-09-20       Impact factor: 4.379

5.  "I'll Be Back": The Resurrection of Dezocine.

Authors:  Wayne E Childers; Magid A Abou-Gharbia
Journal:  ACS Med Chem Lett       Date:  2021-05-19       Impact factor: 4.632

6.  Varenicline in the treatment of tobacco dependence.

Authors:  Karl Fagerström; John Hughes
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.